Gain Therapeutics Inc (GANX)

$1.91 -0.08 (-4.02%)
Market Cap 81.47M
Revenue (ttm) 0.00
Net Income (ttm) -20.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.03
Volume 769,100
Avg Vol 914,854
Day's Range N/A - N/A
Shares Out 42.65M
Stochastic %K 41%
Beta 0.15
Analysts Strong Sell
Price Target $7.20

Company Profile

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 500 1556
Address:
4800 Montgomery Lane, Suite 220, Bethesda, United States
SirDuncan11
SirDuncan11 Jul. 4 at 6:30 PM
$GANX I see zero remaining hurdles to jump. Significant and meaningful partnership or flat out acquisition is truly the next natural step. I wish it could be Monday and so does everyone, but it will happen relatively soon.
1 · Reply
Jwa68
Jwa68 Jul. 4 at 4:20 PM
$GANX GT-00287 is no Kryptonite...Happy Fourth. 🦸‍♂️🇺🇸
0 · Reply
NearEyeOptic
NearEyeOptic Jul. 4 at 4:13 PM
$GANX well not the greatest song about anniversaries ever written it’s still about anniversaries happy birthday America https://www.youtube.com/watch?v=RFSwwfZPVXE
0 · Reply
DonkeyClanbrands
DonkeyClanbrands Jul. 4 at 4:03 PM
$GANX lets talk about $$ for ph2 — clearly the market does not value the science as much as they are concerned about funding ph2.. correct me if iam wrong.. they need $$$ from a partner or a cap raise.. if a partner does not step up we will be right back to 1.50-1.70 but with a further along 02287.. am I delusional or is this possibly and potentially accurate?
2 · Reply
Verassche
Verassche Jul. 4 at 8:30 AM
$GANX ✅astonishing data and phase 2✅more articles, more influencing (super)eyes, more continents (phase 2a: participants across Australia + U.S. + Europe). ✅Ph.D. Khalid Islam's track record ✅CEO: " it's a buy at $10, it's a buy at $15, it's a buy at $20..." ( Note: actual sp: $1,91)➡️ Doubt screams louder than belief. Bubka (pole vault), Bob Beamon (long jump)were unapproachable... not anymore...it's time for Gain to surpass Sotomayor (high jump/2,45m/1993). ➡️Science turned disbelief into belief ...it just needs to sink in a bit more (pile of a-synuclein blocking the sink in- process🫣)➡️ Gain should choose not seek a partnership... Relax. Enjoy your weekend.
0 · Reply
microcapspeculator
microcapspeculator Jul. 3 at 8:06 PM
$GANX Mitochondrial biomarkers are looking like the missing piece. Adding a new biomarker to the Parkinson’s toolbox - University of Luxembourg https://www.uni.lu/lcsb-en/news/mitochondrial-dna-in-blood-adding-a-new-biomarker-to-the-parkinsons-toolbox/ What Is Mitochondrial Complex I and Why Does It Matter? https://gaintherapeutics.com/perspectives/what-is-mitochondrial-complex-i/ While treatments are limited, Gain has recently completed a phase 1 clinical trial for GT-02287, a small molecule GCase modulator. GT-02287 has been shown to repair and rehabilitate lysosomal and mitochondrial function. In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced ER stress, lysosomal and mitochondrial pathology.
0 · Reply
NearEyeOptic
NearEyeOptic Jul. 3 at 7:34 PM
$GANX If Dean Cane can get this slug back to $3, I say we ask the president to put his face the new $3 bill! 😂😂😂 The $2 bill didn't work so well, so the $3 bill is the next logical choice!!! 🤣🤣🤣
1 · Reply
microcapspeculator
microcapspeculator Jul. 3 at 6:48 PM
$GANX Nice shout out by Gain. https://x.com/i/status/2073111761104883763
0 · Reply
plv2000
plv2000 Jul. 3 at 5:18 PM
$GANX ASPro-PD started enrolling patients for ph3. Might be the closest thing to GT-02287. Imagine if a cough medicine can reverse PD. Wow.
1 · Reply
microcapspeculator
microcapspeculator Jul. 3 at 3:31 PM
$GANX As the first patients finish the year long trial many will have aged well over 12 months in Parkinson’s time so any mention of stable and durable means not just a typical 4 to 6 point increase but more like 6 to 8 points. It will be interesting if we get any biomarker data at the end of the study.
1 · Reply
Latest News on GANX
Gain Therapeutics receives FDA clearance of GT-02287 IND application

2026-06-29T20:20:50.000Z - 5 days ago

Gain Therapeutics receives FDA clearance of GT-02287 IND application

Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease

Jun 29, 2026, 4:05 PM EDT - 5 days ago

Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease

Gain Therapeutics Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference

Jun 15, 2026, 7:00 AM EDT - 19 days ago

Gain Therapeutics Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference

Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

Jun 10, 2026, 7:00 AM EDT - 24 days ago

Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

Gain Therapeutics Slides: Corporate presentation

Jun 9, 2026, 7:00 AM EDT - 25 days ago

Gain Therapeutics Slides: Corporate presentation

Gain Therapeutics presents data from Phase 1b study of GT-02287

2026-05-26T14:58:26.000Z - 5 weeks ago

Gain Therapeutics presents data from Phase 1b study of GT-02287

Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

May 26, 2026, 8:00 AM EDT - 5 weeks ago

Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

Gain Therapeutics price target lowered to $8 from $10 at Roth Capital

2026-05-12T19:29:06.000Z - 7 weeks ago

Gain Therapeutics price target lowered to $8 from $10 at Roth Capital

Gain Therapeutics Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 7 weeks ago

Gain Therapeutics Earnings release: Q1 2026

Gain Therapeutics Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 7 weeks ago

Gain Therapeutics Quarterly report: Q1 2026

Gain Therapeutics reports Q1 EPS (13c), consensus (14c)

2026-05-11T11:47:50.000Z - 7 weeks ago

Gain Therapeutics reports Q1 EPS (13c), consensus (14c)

Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update

May 11, 2026, 7:00 AM EDT - 7 weeks ago

Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update

Gain Therapeutics Slides: Corporate presentation

May 5, 2026, 7:00 AM EDT - 2 months ago

Gain Therapeutics Slides: Corporate presentation

Gain Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Gain Therapeutics Proxy statement: Proxy filing

Gain Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Gain Therapeutics Proxy statement: Proxy filing

Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026

Apr 24, 2026, 8:30 AM EDT - 2 months ago

Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026

Gain Therapeutics management to meet with Maxim

2026-04-17T16:20:14.000Z - 2 months ago

Gain Therapeutics management to meet with Maxim

Gain Therapeutics Slides: Corporate presentation

Apr 8, 2026, 7:00 AM EDT - 3 months ago

Gain Therapeutics Slides: Corporate presentation

Gain Therapeutics Annual report: Q4 2025

Mar 26, 2026, 4:00 PM EDT - 3 months ago

Gain Therapeutics Annual report: Q4 2025

Gain Therapeutics Earnings release: Q4 2025

Mar 26, 2026, 4:00 PM EDT - 3 months ago

Gain Therapeutics Earnings release: Q4 2025

Gain Therapeutics reports Q4 EPS (61c), consensus (14c)

2026-03-26T11:26:07.000Z - 3 months ago

Gain Therapeutics reports Q4 EPS (61c), consensus (14c)

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

Mar 26, 2026, 7:00 AM EDT - 3 months ago

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

Gain Therapeutics Transcript: The 38th Annual Roth Conference

Mar 24, 2026, 1:30 PM EDT - 3 months ago

Gain Therapeutics Transcript: The 38th Annual Roth Conference

Gain Therapeutics to Present at the 38th Annual ROTH Conference

Mar 19, 2026, 4:57 PM EDT - 3 months ago

Gain Therapeutics to Present at the 38th Annual ROTH Conference

Gain announces presentations on Phase 1b clinical study of GT-02287

2026-03-18T12:38:06.000Z - 3 months ago

Gain announces presentations on Phase 1b clinical study of GT-02287

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

Mar 18, 2026, 8:15 AM EDT - 3 months ago

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

Gain Therapeutics provides regulatory update on GT-02287

2026-03-12T11:32:59.000Z - 4 months ago

Gain Therapeutics provides regulatory update on GT-02287

Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update

Mar 12, 2026, 7:00 AM EDT - 4 months ago

Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update

Gain Therapeutics Slides: Corporate presentation

Mar 8, 2026, 7:00 AM EDT - 4 months ago

Gain Therapeutics Slides: Corporate presentation

Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 19, 2026, 7:00 AM EST - 4 months ago

Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Jan 7, 2026, 7:00 AM EST - 6 months ago

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Gain Therapeutics Transcript: Study Update

Jan 6, 2026, 10:00 AM EST - 6 months ago

Gain Therapeutics Transcript: Study Update

Gain Therapeutics Press release: Study Update

Jan 6, 2026, 10:00 AM EST - 6 months ago

Gain Therapeutics Press release: Study Update

Gain Therapeutics provides additional data from Phase 1b study of GT-02287

2026-01-06T12:26:07.000Z - 6 months ago

Gain Therapeutics provides additional data from Phase 1b study of GT-02287

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

Jan 6, 2026, 7:00 AM EST - 6 months ago

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

Gain Therapeutics holds a conference call

2025-12-30T16:00:13.000Z - 6 months ago

Gain Therapeutics holds a conference call

Gain Therapeutics price target raised to $10 from $6 at Roth Capital

2025-12-19T18:35:13.000Z - 7 months ago

Gain Therapeutics price target raised to $10 from $6 at Roth Capital

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease

Dec 18, 2025, 4:05 PM EST - 7 months ago

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease

Gain Therapeutic announces Phase 1b study of GT-02287 met prespecified endpoint

2025-12-18T12:10:20.000Z - 7 months ago

Gain Therapeutic announces Phase 1b study of GT-02287 met prespecified endpoint

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease

Dec 18, 2025, 7:00 AM EST - 7 months ago

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease

Gain Therapeutics presents data on GT-02287

2025-11-20T12:05:27.000Z - 8 months ago

Gain Therapeutics presents data on GT-02287

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

Nov 20, 2025, 7:00 AM EST - 8 months ago

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

Gain Therapeutics reports Q3 EPS (15c), consensus (15c)

2025-11-12T12:15:51.000Z - 8 months ago

Gain Therapeutics reports Q3 EPS (15c), consensus (15c)

Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

Nov 12, 2025, 7:00 AM EST - 8 months ago

Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

Gain Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

Gain Therapeutics Earnings release: Q3 2025

Gain Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

Gain Therapeutics Quarterly report: Q3 2025

Gain Therapeutics Registration statement: Registration Filing

Nov 7, 2025, 7:00 AM EST - 8 months ago

Gain Therapeutics Registration statement: Registration Filing

Gain Therapeutics to Present at Neuroscience 2025

Oct 30, 2025, 7:00 AM EDT - 8 months ago

Gain Therapeutics to Present at Neuroscience 2025

Gain Therapeutics price target lowered to $5 from $9 at BTIG

2025-10-16T11:45:35.000Z - 9 months ago

Gain Therapeutics price target lowered to $5 from $9 at BTIG

Gain Therapeutics to Attend the 2025 Maxim Growth Summit

Oct 16, 2025, 7:00 AM EDT - 9 months ago

Gain Therapeutics to Attend the 2025 Maxim Growth Summit

Gain Therapeutics Transcript: Study Result

Oct 14, 2025, 4:00 PM EDT - 9 months ago

Gain Therapeutics Transcript: Study Result

Gain Therapeutics price target raised to $7 from $5 at Maxim

2025-10-07T13:10:58.000Z - 9 months ago

Gain Therapeutics price target raised to $7 from $5 at Maxim

Gain Therapeutics presents initial data from Phase 1b study of GT-02287

2025-10-06T12:36:01.000Z - 9 months ago

Gain Therapeutics presents initial data from Phase 1b study of GT-02287

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®

Oct 6, 2025, 8:15 AM EDT - 9 months ago

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®

Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

Sep 23, 2025, 7:40 AM EDT - 10 months ago

Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease

Sep 18, 2025, 7:41 AM EDT - 10 months ago

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

Sep 4, 2025, 8:00 AM EDT - 10 months ago

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

Gain Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 11 months ago

Gain Therapeutics Quarterly report: Q2 2025

Gain Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 11 months ago

Gain Therapeutics Earnings release: Q2 2025

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

Aug 12, 2025, 7:00 AM EDT - 11 months ago

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

Jul 24, 2025, 8:53 AM EDT - 1 year ago

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

Jul 16, 2025, 9:03 AM EDT - 1 year ago

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

Gain Therapeutics Announces Proposed Public Offering

Jul 15, 2025, 4:36 PM EDT - 1 year ago

Gain Therapeutics Announces Proposed Public Offering

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation

Jun 30, 2025, 4:05 PM EDT - 1 year ago

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation

Gain Therapeutics to Participate in Upcoming Investor Conferences

Jun 10, 2025, 8:00 AM EDT - 1 year ago

Gain Therapeutics to Participate in Upcoming Investor Conferences

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

May 29, 2025, 8:45 AM EDT - 1 year ago

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

Gain Therapeutics Registration statement: Registration Filing

May 28, 2025, 8:00 AM EDT - 1 year ago

Gain Therapeutics Registration statement: Registration Filing

Gain Therapeutics Earnings release: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

Gain Therapeutics Earnings release: Q1 2025

Gain Therapeutics Quarterly report: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

Gain Therapeutics Quarterly report: Q1 2025

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

May 14, 2025, 7:30 AM EDT - 1 year ago

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

May 12, 2025, 7:30 AM EDT - 1 year ago

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

May 1, 2025, 7:30 AM EDT - 1 year ago

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

Apr 30, 2025, 7:45 AM EDT - 1 year ago

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

Gain Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Gain Therapeutics Proxy statement: Proxy Filing

Gain Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Gain Therapeutics Proxy statement: Proxy Filing

Gain Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Gain Therapeutics Proxy statement: Proxy Filing

Gain Therapeutics Announces Poster Presentation at AD/PD 2025

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Gain Therapeutics Announces Poster Presentation at AD/PD 2025

Gain Therapeutics Annual report: Q4 2024

Mar 27, 2025, 1:30 PM EDT - 1 year ago

Gain Therapeutics Annual report: Q4 2024

Gain Therapeutics Earnings release: Q4 2024

Mar 27, 2025, 1:30 PM EDT - 1 year ago

Gain Therapeutics Earnings release: Q4 2024

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease

Mar 14, 2025, 7:45 AM EDT - 1 year ago

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

Mar 6, 2025, 7:55 AM EST - 1 year ago

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

Feb 6, 2025, 8:45 AM EST - 1 year ago

Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

Gain Therapeutics To Participate in Upcoming Investor Conferences

Feb 5, 2025, 8:30 AM EST - 1 year ago

Gain Therapeutics To Participate in Upcoming Investor Conferences

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease

Dec 23, 2024, 7:30 AM EST - 1 year ago

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease

Gain Therapeutics To Present At Biotech Showcase 2025

Dec 11, 2024, 8:30 AM EST - 1 year ago

Gain Therapeutics To Present At Biotech Showcase 2025

Gain Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 12:00 AM EST - 1 year ago

Gain Therapeutics Quarterly report: Q3 2024

Gain Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 12:00 AM EST - 1 year ago

Gain Therapeutics Earnings release: Q3 2024

Gain Therapeutics Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 15, 2024, 12:00 PM EDT - 1 year ago

Gain Therapeutics Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

Gain Therapeutics to Participate at Upcoming Investor Conferences

Oct 3, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics to Participate at Upcoming Investor Conferences

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Sep 26, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Aug 29, 2024, 7:30 AM EDT - 2 years ago

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Gain Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Gain Therapeutics Quarterly report: Q2 2024

Gain Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Gain Therapeutics Earnings release: Q2 2024

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Aug 8, 2024, 7:30 AM EDT - 2 years ago

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease

Jul 9, 2024, 7:00 AM EDT - 2 years ago

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease

Gain Therapeutics Transcript: Status Update

Jul 1, 2024, 8:30 AM EDT - 2 years ago

Gain Therapeutics Transcript: Status Update

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

Jun 28, 2024, 4:39 PM EDT - 2 years ago

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

SirDuncan11
SirDuncan11 Jul. 4 at 6:30 PM
$GANX I see zero remaining hurdles to jump. Significant and meaningful partnership or flat out acquisition is truly the next natural step. I wish it could be Monday and so does everyone, but it will happen relatively soon.
1 · Reply
Jwa68
Jwa68 Jul. 4 at 4:20 PM
$GANX GT-00287 is no Kryptonite...Happy Fourth. 🦸‍♂️🇺🇸
0 · Reply
NearEyeOptic
NearEyeOptic Jul. 4 at 4:13 PM
$GANX well not the greatest song about anniversaries ever written it’s still about anniversaries happy birthday America https://www.youtube.com/watch?v=RFSwwfZPVXE
0 · Reply
DonkeyClanbrands
DonkeyClanbrands Jul. 4 at 4:03 PM
$GANX lets talk about $$ for ph2 — clearly the market does not value the science as much as they are concerned about funding ph2.. correct me if iam wrong.. they need $$$ from a partner or a cap raise.. if a partner does not step up we will be right back to 1.50-1.70 but with a further along 02287.. am I delusional or is this possibly and potentially accurate?
2 · Reply
Verassche
Verassche Jul. 4 at 8:30 AM
$GANX ✅astonishing data and phase 2✅more articles, more influencing (super)eyes, more continents (phase 2a: participants across Australia + U.S. + Europe). ✅Ph.D. Khalid Islam's track record ✅CEO: " it's a buy at $10, it's a buy at $15, it's a buy at $20..." ( Note: actual sp: $1,91)➡️ Doubt screams louder than belief. Bubka (pole vault), Bob Beamon (long jump)were unapproachable... not anymore...it's time for Gain to surpass Sotomayor (high jump/2,45m/1993). ➡️Science turned disbelief into belief ...it just needs to sink in a bit more (pile of a-synuclein blocking the sink in- process🫣)➡️ Gain should choose not seek a partnership... Relax. Enjoy your weekend.
0 · Reply
microcapspeculator
microcapspeculator Jul. 3 at 8:06 PM
$GANX Mitochondrial biomarkers are looking like the missing piece. Adding a new biomarker to the Parkinson’s toolbox - University of Luxembourg https://www.uni.lu/lcsb-en/news/mitochondrial-dna-in-blood-adding-a-new-biomarker-to-the-parkinsons-toolbox/ What Is Mitochondrial Complex I and Why Does It Matter? https://gaintherapeutics.com/perspectives/what-is-mitochondrial-complex-i/ While treatments are limited, Gain has recently completed a phase 1 clinical trial for GT-02287, a small molecule GCase modulator. GT-02287 has been shown to repair and rehabilitate lysosomal and mitochondrial function. In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced ER stress, lysosomal and mitochondrial pathology.
0 · Reply
NearEyeOptic
NearEyeOptic Jul. 3 at 7:34 PM
$GANX If Dean Cane can get this slug back to $3, I say we ask the president to put his face the new $3 bill! 😂😂😂 The $2 bill didn't work so well, so the $3 bill is the next logical choice!!! 🤣🤣🤣
1 · Reply
microcapspeculator
microcapspeculator Jul. 3 at 6:48 PM
$GANX Nice shout out by Gain. https://x.com/i/status/2073111761104883763
0 · Reply
plv2000
plv2000 Jul. 3 at 5:18 PM
$GANX ASPro-PD started enrolling patients for ph3. Might be the closest thing to GT-02287. Imagine if a cough medicine can reverse PD. Wow.
1 · Reply
microcapspeculator
microcapspeculator Jul. 3 at 3:31 PM
$GANX As the first patients finish the year long trial many will have aged well over 12 months in Parkinson’s time so any mention of stable and durable means not just a typical 4 to 6 point increase but more like 6 to 8 points. It will be interesting if we get any biomarker data at the end of the study.
1 · Reply
littlecjc016
littlecjc016 Jul. 3 at 3:28 PM
$GANX
0 · Reply
RealAvidTrader
RealAvidTrader Jul. 3 at 2:39 PM
$GANX Amazing
0 · Reply
FRF
FRF Jul. 3 at 2:09 PM
$ANVS I did some basic research on $GANX. It has different mechanisms of action. It is still earlier stage. I took a very small position.
3 · Reply
john_Ennis
john_Ennis Jul. 3 at 1:44 PM
$GANX even superman gets 4th of July off. See you all next week
0 · Reply
Jwa68
Jwa68 Jul. 3 at 1:24 PM
$GANX Truth, Justice, the American Way, and GT-00287. 🇺🇸👍
1 · Reply
whodat2025
whodat2025 Jul. 3 at 12:25 PM
$GANX
0 · Reply
microcapspeculator
microcapspeculator Jul. 3 at 12:16 PM
$GANX This is a pretty good report. Explains why GT-02287 can work will the other GCase activators may not like Bial. https://x.com/i/status/2072680043789066666
0 · Reply
mwb1
mwb1 Jul. 3 at 11:34 AM
$GANX Gain has been puzzlingly and frustratingly invisible. This is the sort of thing that starts some traction. I don't know if GT-02287 will work for Cane's father, but we have enough information to know that it will help in some, many, or possibly even most cases. It's not too soon for the word to get out.
0 · Reply
Jwa68
Jwa68 Jul. 3 at 5:11 AM
$GANX Superman himself has spoken! Remember how I suggested an epiphany was coming. How those who know, know and the circle is growing. How Parkinson's is deeply personal to many. How GT-00287 could impact the lives of so many and their loved ones, the world as a whole. How it was only a matter of time until obscurity may become notoriety. Well Dean Cane, actor, celebrity, Podcaster, American bad ass, true patriot, close friends with Dr. Oz, President Trump and RFK Jr. amongst many other important politicians and celebrities, and son of Parkinson's patient, is one of those personally affected. Because he cares and has a huge platform, he may just helped flip that long awaited switch. He just told the world with his nearly 1M Twitter(X) about Gain and GT-00287 and how important it is for people like him, his father who is his hero, and so many others. Thank you Dean...🦸‍♂️🇺🇸🙏 https://x.com/i/status/2072888542611595517
5 · Reply
zampy
zampy Jul. 3 at 4:01 AM
$GANX This asset will be gobbled up like pac man the next 6 months...
1 · Reply
NearEyeOptic
NearEyeOptic Jul. 3 at 3:14 AM
$GANX we're up 2 cents over the past 3 months 😒🙄😒 Apparently, good data is good, but financing is golden. Let's get it done in Q3.
0 · Reply
littlecjc016
littlecjc016 Jul. 3 at 2:04 AM
$GANX
0 · Reply